HLX04 is a bevacizumab biosimilar developed by Henlius independently in accordance with Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative), which can be used in the treatment of advanced, metastatic or recurrent non-small cell lung cancer(NSCLC) and metastatic colorectal cancer(mCRC).
Serplulimab injection is an innovative anti-PD-1 mAb independently developed by Henlius. Up to now, Serplulimab have been approved for clinical trials in China, the United States, the European Union, as well as other countries and regions.
HLX01 ( rituximab injection) is the first monoclonal antibody (mAb) biosimilar independently developed by Henlius and the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative).
Recently, Biodrugs published the results of the global multicentre Phase 3 clinical trial (HLX02-BC01, NCT03084237 and EudraCT: 2016-000206-10) of 汉曲优®, (trastuzumab, EU brand name: Zercepac®) which was led by Professor Binghe Xu
At 11:00 p.m on November 19, 2020 (Beijing time), Fosun Pharma, together with two internationally renowned malaria experts, once again hosted a brilliant online academic conference for nearly 700 African medical workers, sharing the latest scientific advances in the prevention of maternal and childhood Malaria, and conducting a lively online Q&A session on related topics.
On November 22, 2020, the first "Ankylosing Spondylitis Standardized Medical Center (ASSC)" project in China, sponsored by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID),
Recently, the study results of HLX02-HV01 (Clinical Trial No.: NCT02581748), a phase 1 clinical trial of Henlius HLX02 HAN QU YOU® (Trastuzumab, EU trade name: Zercepac®), were published in Cancer Chemotherapy and Pharmacology, a well-known journal in the field of cancer therapy, and the study was led by Professor Zhang Quanying from the Second Affiliated Hospital of Soochow University. The publication of the results of the HAN QU YOU® Phase 1 study indicates the recognition of the quality and data of the clinical study by peer review, which is an affirmation of the development level of high-quality biosimilars produced in China.
At this meeting, Henlius for the first time released the Phase 3 study results of its bevacizumab biosimilar HLX04 (recombinant humanised anti-VEGF monoclonal antibody injection), which was developed by the company independently.
